New incident report
Incident Report Number: 2023-4162
Registrant Reference Number: 2023-CA-000244
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: MANITOBA
PMRA Registration No. 29930 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard OneSpot Flea and Tick Cat Drops
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Animal's Owner
Cat / Chat
Domestic Longhair
1
Male
0.25
1.0
kg
Skin
>15 min <=2 hrs / >15 min <=2 h
<=30 min / <=30 min
System
Unknown / Inconnu
No
No
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 29-Jun-2023, a 0.25 year old, approximately 1.0 kilogram, intact, male, Domestic Longhair cat, in unknown condition, with no known concomitant medical conditions, was administered 1 tube of Hartz UltraGuard OneSpot Flea and Tick Cat Drops (S Methoprene) via the topical route by the animal owner. Approximately 1 minute after application, the cat developed scratching at its skin and rubbing on nearby surfaces. The cat also developed drooling that resolved after approximately 5 minutes. He was then bathed with an unknown amount of unspecified soap by the animal owner. Approximately 20 minutes post bathing, the cat developed lethargy. The cat had not been evaluated by a veterinarian and no medical treatment had been performed. The clinical signs continued. Monitoring for persistent or worsening signs was recommended. No further information was received in this case.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.